Evidence map›Paper›PMID 39526512›Full record

ReviewSmall methods2025

Advancing Topoisomerase Research Using DNA Nanotechnology.

Doron Yesodi, Adi Katz, Yossi Weizmann

Abstract readReview
In one paragraph

Review in Small methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Doron YesodiDepartment of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.
Adi KatzDepartment of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.
Yossi WeizmannDepartment of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.ORCID https://orcid.org/0000-0002-3467-990X

Funding

ISF-NSFC Joint Research Program 3258/20
6 · The paper itself

Abstract

In this Perspective, the use of DNA nanotechnology is explored as a powerful tool for studying a family of enzymes known as topoisomerases. These enzymes regulate DNA topology within a living cell and play a major role in the pharmaceutical field, serving as anti-cancer and anti-bacterial targets. This Perspective will provide a short historical overview of the methods employed in studying these enzymes and emphasizing recent advancements in assays using DNA nanotechnology. These innovations have substantially improved accuracy and expanded the understanding of enzyme activity. This perspective will showcase the versatile utility of DNA nanotechnology in advancing scientific knowledge and its application in exploring new drug candidates, particularly in the study of topoisomerase enzymes.

Indexed as

DNADNA TopoisomerasesNanotechnologyHumansDNADNA TopoisomerasesDNA nanotechnologyDNA topologydrug discoveryenzymatic assayshigh‐thruput screeningtopoisomerases

Identifiers

PMID39526512
PMCPMC12182894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.